Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)

Trial Profile

Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms RE2SPOND
  • Sponsors AstraZeneca; Forest Laboratories
  • Most Recent Events

    • 24 May 2017 Results of pooled analysis from REACT and RE2SPOND studies evaluating the efficacy of roflumilast in the overall population and in patients with a history of COPD-related hospitalization presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results assessing effects of roflumilast on cough and sputum production, EXACT-PRO symptom subdomains, presented at the 113th International Conference of the American Thoracic Society
    • 15 Dec 2016 Planned locations also included Germany, United Kingdom, Chile and Latvia as per European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top